Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.

Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma. Haematologica. 2017 Aug 03;: Authors: Jung SH, Lee SE, Lee M, Kim SH, Yim SH, Kim TW, Min CK, Chung YJ PMID: 28775122 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28775122?dopt=Abstract

Source: Haematologica - August 3, 2017 Category: Hematology Authors: Jung SH, Lee SE, Lee M, Kim SH, Yim SH, Kim TW, Min CK, Chung YJ Tags: Haematologica Source Type: research

More News: Dexamethasone | Hematology | Myeloma | Revlimid